Physician profile
Gina C Ridder
NPI 1629045448
$2,389.40
in general payments reported to CMS, 2019-2025
11 companies · $286 in 2025
The $286 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $309 · 2020: $182 · 2021: $307 · 2022: $627 · 2023: $243 · 2024: $436 · 2025: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $964.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $964.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $506.38 | 2022-2024 | |
| Alcon Vision LLC | $432.52 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $364.12 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $232.91 | 2020-2023 | Acuvue |
| Bausch & Lomb Americas INC. | $232.75 | 2022-2024 | Infuse, Miebo, Xiidra |
| Coopervision INC. | $190.78 | 2022-2025 | Myday Contact Lens |
| Abbvie INC. | $122.55 | 2025 | |
| Sun Pharmaceutical Industries INC. | $117.42 | 2022 | |
| Sight Sciences, INC. | $108.10 | 2025 | Tearcare System |
| Ivantis, INC | $67.79 | 2021 | |
| Allergan, INC. | $14.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Ridder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.